The use of cannabidiol in patients with Lennox-Gastaut syndrome and Dravet syndrome in the UK Early Access Program: A retrospective chart review study.

ABSTRACT:

Purpose

To evaluate clinical outcomes from the UK Early Access Program in patients aged 2-17 years with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) treated with plant-derived highly purified cannabidiol (CBD; Epidyolex®; 100 mg/mL oral solution).

Methods

Retrospective chart review of data collected from baseline (1 month before CBD treatment initiation) until 12 months' treatment, CBD discontinuation, death, or loss to follow up.

Results

At baseline, all 26 patients enrolled (LGS, n = 17; DS, n = 9; male, 73 %; mean [range] age, 11.8 [3.0-17.0] years) experienced motor seizures; 92 % were taking ≥ 1 antiseizure medication. Median (IQR) CBD dosage at 6 months (6 M; n = 12) was 6.0 (2.7) mg/kg/day, and 12 months (12 M; n = 9) 7.3 (2

SUBMITTER: Eltze C 

PROVIDER: S-EPMC11786083 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature